Adherium Secures A$887K R&D Tax Refund Plus NZ$242K Claim to Boost Cash Reserves
Adherium Limited is an international Respiratory eHealth company specializing in improving medication adherence and patient outcomes in asthma and COPD through connected technology. Their flagship solution, the Hailie® Smartinhaler®, seamlessly integrates with a secure cloud platform, providing real-time data on inhaler usage for both patients and healthcare professionals. This technology enables precise remote monitoring, helping clinicians optimize treatment plans while empowering patients to manage their respiratory health more effectively.
The company’s offerings are particularly suited to the evolving landscape of telehealth and remote patient monitoring (RPM), which have accelerated in adoption due to recent healthcare shifts and favorable US reimbursement structures. By enabling data-driven clinical decisions and supporting adherence in difficult-to-treat and severe respiratory cases, Adherium’s solutions help reduce preventable healthcare costs, which are estimated to reach $34 billion annually in the US due to medication non-adherence.
Adherium’s Smartinhaler® technology aligns with global clinical guidelines that recommend electronic monitoring tools to assess adherence before making therapy changes in challenging asthma cases. Their continuous innovation, including the introduction of sensors that capture additional physiological parameters, positions Adherium at the forefront of digital respiratory health. By collaborating with patients, providers, and payers, Adherium aims to deliver value across the healthcare ecosystem and improve quality of life for those managing chronic respiratory conditions.
© 2026 StockWire X Pty Ltd. All rights reserved.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.